The determination of propoxyphene, norpropoxyphene, and methadone in postmortem blood and tissues by high-performance liquid chromatography

New polyvinyl chloride membrane electrode without inner reference solution for the determination of methadone

A PVC membrane electrode, without inner reference solution, based on an ion association extraction system responding to methadone (MD) is described. It incorporates a methadone-tetrakis(4-chlorophenyl)borate ion-pair complex in 2-nitrophenyloctyl ether. The prepared electrode exhibits a near Nernstian response (59.5 mV per decade) over the concentration range 2.5 x 10(-5)-10(-1) M MD in solutions of pH 2.0-9.0. The reproducibility of the electrode potentials was +/-1 mV by day during at least 6 months. Response time was about 5 s for MD concentrations between 10(-5) and 10(-1) M. Determinations of MD in pharmaceutical preparations (tablets and syrups) by direct potentiometry gave an average recovery of 99.3% (w/w) and a mean S.D. of 1.5% (w/w).

AAS and AES determination of furaltadone, methadone and trazodone in pharmaceutical formulations

Ion-associate complexes of furaltadone, methadone and trazodone hydrochlorides with [Cd(SCN)(4)](2-) and [Zn(SCN)(4)](2-) were precipitated and the excess unreacted cadmium or zinc complex was determined. A new method using atomic emission and atomic absorption spectrometry for the determination of the above drugs in pure solutions and in pharmaceutical preparations is given. The drugs can be determined by the affort method in the ranges 7.2-72.16, 6.9-69.18 and 8.1-81.6 microg/ml solutions of the three drugs, respectively.

Novel high-performance liquid chromatographic and solid-phase extraction methods for quantitating methadone and its metabolite in spiked human urine

A novel solid-phase extraction (SPE) method and HPLC method were developed for the determination of methadone and its metabolite from spiked human urine. For sample cleanup, a spiked urine sample was pretreated with phosphoric acid followed by a well-thought-out SPE method using a 10-mg Oasis HLB 96-well extraction plate. In this SPE method, the concentration of methanol as well as the pH are optimized to preferentially isolate the analytes of interest from the sample matrix. Low elution volumes (200 microl) are achieved; this eliminates evaporation and reconstitution of the sample solution. Recoveries from human urine matrix were greater than 91% with RSD values less than 4.5%. For the HPLC analysis, the separation was obtained using a SymmetryShield RP18 column with a mobile phase of 0.1% TFA-methanol (60:40, v/v). Good peak shapes were obtained without the need of addition of any competing reagent to the mobile phase. Additionally, significant signal-to-noise enrichment was achieved by diluting the final SPE eluates four-fold with water.

Screening for drugs of abuse (II): Cannabinoids, lysergic acid diethylamide, buprenorphine, methadone, barbiturates, benzodiazepines and other drugs

Requirements for the provision of an efficient and reliable service for drugs of abuse screening in urine have been summarized in Part I of this review. The requirements included rapid turn-around times, good communications between requesting clinicians and the laboratory, and participation in quality assessment schemes. In addition, the need for checking/confirmation of positive results obtained for preliminary screening methods was stressed. This aspect of the service has assumed even greater importance with widespread use of dip-stick technology and the increasing number of reasons for which drug screening is performed. Many of these additional uses of drug screening have possible serious legal implications, for example, screening school pupils, professional footballers, parents involved in child custody cases, persons applying for renewal of a driving licence after disqualification for a drug-related offence, doctors seeking re-registration after removal for drug abuse, and checking for compliance with terms of probation orders; as well as pre-employment screening and work-place testing. In many cases these requests will be received from a general practitioner or drug clinic with no indication of the reason for which testing has been requested. This also raises the serious problems of a chain of custody, provision of two samples, stability of samples, and secure and lengthy storage of samples in the laboratory-samples may be requested by legal authorities several months after the initial testing. The need for confirmation of positive results is now widely accepted but it may be equally important to confirm unexpected negative results. Failure to detect the presence of maintenance drugs may lead to the patient being discharged from a drug treatment clinic and, if attendance at the clinic is one of the terms of continued employment, to dismissal. It seems likely that increasing abuse of drugs and the efforts of regulatory authorities to control this, will lead to the manufacture of more designer drugs. Production of substituted phenethylamines was facilitated by the drug makers' cook book, 'PIHKAL' (Phenethylamines I Have Known And Loved) by Dr Alexander Shulgin and Ann Shulgin, and production of substituted tryptamines is promised in their next book, TIHKAL. Looking to the future, laboratories will need to ensure that they can detect and quantitate an ever-increasing number of drugs and related substances. The question of confidence in results of drugs of abuse testing raised in 1993 by Watson has assumed even greater importance as a result of attention focused on the OJ Simpson trial in Los Angeles. Toxicological investigations are likely to be challenged more frequently in the future. Even if analyses have been performed by GC-MS, there is a need to establish the level of match between the spectrum of the unknown substance and a library spectrum which is considered acceptable for legal purposes. It will also be essential to ensure that computer libraries contain spectra for all substances likely to be encountered in drugs of abuse screening.

Liquid chromatographic-thermospray tandem mass spectrometric quantitative analysis of some drugs with hypnotic, sedative and tranquillising properties in whole blood

Results are presented of a liquid chromatographic-thermospray tandem mass spectrometric method of analysing different drugs in whole blood. Substances with hypnotic, sedative and tranquillising properties from the benzodiazepine, the thioxanthene, the butyrophenone, the methadone and the diphenylbutylpiperidine groups were investigated. It appears that ten to hundred times lower detection limits for the substances in whole blood can be reached with this method compared with methods more commonly used. Detection limits in the range 10-100 pg per injection (equivalent to 0.05-0.5 ng/ml whole blood) were reached for the majority of the compounds.

Determination of dextropropoxyphene and norpropoxyphene in plasma by high-performance liquid chromatography

A simple and sensitive procedure for the routine assay of the analgesic drug dextropropoxyphene and its main metabolite, norpropoxyphene, in plasma is described. After liquid-liquid extraction from alkalinized plasma and back-extraction into a small volume of an acidic aqueous phase, the aqueous phase was injected into a column packed with 3-microns octadecylsilica particles. Ultraviolet absorbance detection at 210 nm was used. Concentrations down to 2 nM could be determined for both compounds; at this level, the intra-assay coefficient of variation was 5%.